Phase III Clinical Trial: 'Evaluation of the Combination of Nimotuzumab and Cisplatin-Vinorelbine in First Line Chemotherapy in the Survival of Patients With Recurring-Persistent Cervical Carcinoma'
Phase of Trial: Phase III
Latest Information Update: 31 Aug 2016
Price : $35 *
At a glance
- Drugs Nimotuzumab (Primary) ; Cisplatin; Vinorelbine
- Indications Cervical cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 13 Apr 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 03 Apr 2014 Treatment table very unclear.